The global ophthalmic products market size was estimated at $33.5 billion in 2021, with the US ophthalmic drugs market alone valued at $12 billon (2021). We are increasing our research and development activities on novel ophthalmic therapies, focusing on addressing patients’ needs in inflammation, glaucoma, and dry eye disease (DED).

Aucta’s ophthalmic portfolio includes NDA 505(b)(2) and generic 505j products based on platform such as nanotechnology or innovative drug device combination.  Drug-delivery systems utilizing nanoparticles are complex dosage forms with a sub-micron dispersion system. By using a small amount of surfactant or other carriers as suspending agents, the systems can deliver active drugs with reduced particle size and increased surface area, therefore improving the bioavailability of poorly soluble drugs. Furthermore, new devices such as Blow Fill Seal (BFS) single-dose preparations or multi-dose configurations were evaluated with our formulation to improve drug delivery.